Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 33.22% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 2.94% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 4.50% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 26.82% |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 66.11% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -17.90% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -30.70% |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 253.53% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -109.16% |
| 10 | Akebia Therapeutics | 235.00 Mn | 72.40 Mn | 41.25 Mn | 30.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.42% |
| Dec 31, 2025 | -23.47% |
| Sep 30, 2025 | 26.20% |
| Jun 30, 2025 | -79.68% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | 31.33% |
| Sep 30, 2024 | 30.44% |
| Jun 30, 2024 | 53.07% |
| Mar 31, 2024 | 36.35% |
| Dec 31, 2023 | 26.14% |
| Sep 30, 2023 | 37.71% |
| Jun 30, 2023 | 60.09% |
| Mar 31, 2023 | 23.80% |
| Dec 31, 2022 | 58.29% |
| Sep 30, 2022 | 0.30% |
| Jun 30, 2022 | 35.83% |
| Mar 31, 2022 | 4.28% |
| Dec 31, 2021 | -5.45% |
| Sep 30, 2021 | -31.73% |
| Jun 30, 2021 | -34.58% |